IMMUNOLOGY2026™ Conference Recordings For Attendees-In situ Transglutaminase 2-mediated Crosslinking of Engineered IL-7 to the Tumor Matrix Enhances Immunotherapy and Anti-PD-1 Response

In situ Transglutaminase 2-mediated Crosslinking of Engineered IL-7 to the Tumor Matrix Enhances Immunotherapy and Anti-PD-1 Response

Back to course

Video Transcription

Video Summary

Angie Chun described a tumor-selective cytokine delivery platform using transglutaminase 2 (TG2), an enzyme active mainly in tumors and inflamed tissues. By fusing cytokines to a TG2 substrate tag, the therapy is covalently cross-linked and retained in tumor extracellular matrix, reducing systemic exposure. In mouse models, TG2-tagged mCherry accumulated specifically in tumors, and TG2-tagged IL-7 improved survival, especially with anti-PD-1 therapy. The approach also worked in orthotopic liver, lung, and ovarian cancer models, with strong immune activation and minimal toxicity. The platform may be adaptable to other cytokines, chemokines, and inflammatory diseases.

Meta Tag

Date April 16, 2026 10:30 AM - 10:45 AM

Room 157

Session Novel Tumor Therapies

Speaker Angie Chun

Track Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

Year 2026

Keywords

tumor-selective cytokine delivery

transglutaminase 2

TG2-tagged IL-7

anti-PD-1 therapy

tumor extracellular matrix

April 16, 2026 10:30 AM - 10:45 AM

157

Novel Tumor Therapies

Angie Chun

Tumor Immunology: Checkpoints, Prevention, And Treatment (TIPT)

2026